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Although chromosomal instability (CIN) is a common phe-
nomenon in cleavage-stage embryogenesis following in vitro 
fertilization (IVF)1–3, its rate in naturally conceived human 
embryos is unknown. CIN leads to mosaic embryos that con-
tain a combination of genetically normal and abnormal cells, 
and is significantly higher in in  vitro-produced preimplanta-
tion embryos as compared to in  vivo-conceived preimplan-
tation embryos4. Even though embryos with CIN-derived 
complex aneuploidies may arrest between the cleavage and 
blastocyst stages of embryogenesis5,6, a high number of 
embryos containing abnormal cells can pass this strong selec-
tion barrier7,8. However, neither the prevalence nor extent of 
CIN during prenatal development and at birth, following IVF 
treatment, is well understood. Here we profiled the genomic 
landscape of fetal and placental tissues postpartum from 
both IVF and naturally conceived children, to investigate the 
prevalence and persistence of large genetic aberrations that 
probably arose from IVF-related CIN. We demonstrate that 
CIN is not preserved at later stages of prenatal development, 
and that de  novo numerical aberrations or large structural 
DNA imbalances occur at similar rates in IVF and naturally 
conceived live-born neonates. Our findings affirm that human 
IVF treatment has no detrimental effect on the chromosomal 
constitution of fetal and placental lineages.
CIN is a common event in human cleavage-stage embryogenesis, 
resulting in a high frequency of chromosomal mosaicism in IVF 
embryos1–3, and probably provides an explanation for the low suc-
cess rate per embryo transfer of IVF9. Strikingly, most IVF embryos 
are mixtures of euploid and aneuploid cells and only a low fraction 
of IVF embryos contains a normal karyotype in all blastomeres1,10. 
Between the cleavage and blastocyst stages of embryogenesis, CIN 
may cause complex aneuploidies and the arrest of many embryos5,6. 
Even after this substantial selection, genetically aberrant cells can 
be preserved at high frequency in the developing blastocysts, such 
that about 40% of blastocysts have been reported to be uniformly 
euploid7,8. Despite the high prevalence of human IVF embryos 
with aberrant chromosomal configurations, its clinical implica-
tions are poorly understood. Recently, we established Bos taurus 
as a model organism to study CIN at cleavage-stage embryogen-
esis11 and showed that CIN in in vitro-produced embryos is signifi-
cantly higher in prevalence when compared to in  vivo-conceived 
embryos4, raising alarming concern about the effect of suboptimal 
in vitro environment on embryonic genetic integrity. However, the 
fate of aberrant cells after cleavage-stage embryogenesis is not clear 
and it remains impossible to investigate naturally conceived human 
embryos in vivo.
Cell lineages containing genetic aberrations in mosaic cleavage-
stage embryos have been speculated to survive in the trophecto-
derm, having little or no influence on the composition of the inner 
cell mass and its subsequent fetal development12. This possibil-
ity is in accordance with the confined placental mosaicism found 
in approximately 1–2% of ongoing natural pregnancies13 and the 
low prevalence of genetic mosaicism in postnatal and adult DNA 
samples14. Furthermore, euploid blastomeres may outgrow blasto-
meres with chromosomal aberrations15, allowing normal embry-
onic development and birth. This view of preferential selection of 
normal cells is supported by recent studies reporting the birth of 
healthy babies after intrauterine transfer of genetically mosaic IVF 
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embryos16,17. In addition, a recent report described lineage-specific 
fate in chimeric mouse embryos. That report demonstrated that dif-
ferent mechanisms act on aneuploid cells in fetal or placenta lin-
eages such that apoptotic depletion of aneuploid cells occurs in fetal 
lineage, whereas aneuploid cells in placenta persist but slow down 
their divisions18.
To investigate the persistence of IVF-related CIN, we profiled 
de novo DNA copy number alterations in DNA samples extracted 
from cord blood cells and placental tissue, which are derived from 
embryonic and extra-embryonic cell lineages, respectively, of both 
IVF and naturally conceived neonates using haplarithmisis3 and 
molecular karyotyping. Importantly, the transferred embryos of 
IVF newborns were neither screened nor counterselected for chro-
mosomal aneuploidy status before intrauterine transfer. Following 
live birth, we scrutinized genome-wide single nucleotide polymor-
phism (SNP) profiles in DNA from the father, mother, placenta and 
neonate umbilical cord blood of 111 families (quartets; Fig. 1a), 
of which 49 and 62 quartets were from IVF and natural pregnan-
cies, respectively. In the IVF cohort, the infertile patients underwent 
fresh or frozen IVF (n = 32) or intracytoplasmic sperm injection 
(ICSI, n = 17) embryo transfer, with about four out of five embryos 
transferred on days 2/3 (n = 38, 77.5%) and the remainder on days 
5/6 at the blastocyst stage (n = 11, 22.5%). These quartets were fur-
ther subdivided based on birth weight at delivery, with 48 IVF and 
50 natural conception families categorized as ‘appropriate for gesta-
tional age’ (AGA), and one IVF and 12 natural conception families 
as ‘small for gestational age’ (SGA) (Supplementary Tables 1 and 2). 
DNA copy number variants (CNVs) were classified by whether 
they were found exclusively in a single sample or a few to all sam-
ples within a quartet. This approach empowered our analysis and 
allowed us to differentiate inherited CNVs (present in either or 
both parents, umbilical cord blood and placenta), de novo CNVs 
(present in placenta and umbilical cord blood only) and placental 
de novo CNVs (present in placenta only). CNVs were detected by 
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Fig. 1 | Haplarithmisis reveals genetic mosaicism with parent-of-origin information. a, Schematic representation of a quartet. b, Haplarithmisis can 
determine the maternal DNA contribution to bulk placental DNA sample (see Methods). c, A maternally inherited CNV (red arrows) and placental 
de novo CNV with paternal origin found on Chr 5 of P070 (purple arrow). BAF (B allele frequency) of a SNP is the signal intensity of allele B over signal 
intensities of both expected A and B alleles for that SNP BAF ¼ BAþB
 
I
, and logR (relative copy number) of that SNP is the base 2 logarithm of the summed 
normalized signal intensities of both alleles over expected signal intensity values logR ¼ RsampleRexpected
 
I
. d, Overview of de novo CNVs found in this study  
(see also Source data). G, gains; L, losses (as shown in Table 1).
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the combined use of relative copy number (logR) values, B allele fre-
quency (BAF) and parent-of-origin haplotypes (haplarithms). The 
latter analysis allowed us to account for maternal DNA contribution 
in placental tissue (Fig. 1b and Extended Data Fig. 1), to identify the 
parental origin of de novo CNVs (Fig. 1c and Table 1) and to more 
accurately estimate the level of mosaicism of CNVs within the DNA 
sample (Fig. 2a,b and Table 1).
We detected de novo large CNVs (>100 kilobase pairs (kb)) in 
placental genomes of 12 families; of the 15 detected aberrations, 
four were also present in newborns and 11 were exclusively pres-
ent in the placenta. We did not detect any CNVs present only 
in umbilical cord blood DNA, which would indicate a genomic 
alteration in the neonate only. The mosaic (n = 12) de novo CNVs 
were 5–70% mosaic (Table 1) and were, together with de  novo 
nonmosaic CNVs (n = 3), randomly located across the genome 
(Fig. 1d). Our analysis showed comparable prevalence (P = 0.327 
odds ratio test or P = 0.775 Pearson’s chi-square test) of de novo 
CNVs in both cohorts with AGA: six of the 50 families with natu-
rally conceived neonates (12.0%) and in three of the 48 families 
with IVF neonates (6.3%) (Table 1). When IVF with fresh and fro-
zen embryo transfers was compared to ICSI fresh/frozen embryo 
transfers, similar proportions of mosaic de novo CNV cases were 
found (6.3%, 2/32 and 5.9%, 1/17, respectively, P = 0.96 odds ratio 
test), indicating that the modes of fertilization (IVF versus ICSI) 
and embryo freezing are unlikely to influence the rate of large 
CNVs in fetal and placental lineages.
We found three partial trisomies with different levels of mosa-
icism in family P172 from the naturally conceived cohort, and a 
mosaic full-chromosome trisomy in family P106 from the IVF 
cohort (Fig. 2a,b, Table 1 and Extended Data Figs. 2 and 3), showing 
mosaicism of 5–25%. We obtained biopsies from two other spatially 
distinct locations, applied haplarithmisis and confirmed the results 
using droplet digital PCR (ddPCR) (Fig. 2c and Supplementary 
Table 3). The partial mosaic trisomies on chromosome 6 (Chr 6, 
22.4 Mb), Chr 9 (5.8 Mb) and Chr 21 (22.0 Mb) of P172 were 
not present in the other placental biopsies (Fig. 2c and Extended 
Data Fig. 2). In contrast, the full Chr 2 mosaic trisomy was present 
in all P106 placental biopsies (Fig. 2c and Extended Data Fig. 3). 
This result indicates that the mosaic Chr 2 trisomy arose as CIN 
in the early cleavage-stage embryo but segregated into the placen-
tal lineage only (Fig. 3 and Table 1), because it was present across 
different parts of the placenta with the same degree of mosaicism. 
The presence of the low-degree mosaic Chr 2 trisomy reinforces 
an earlier observation in mouse embryos, which suggested a pro-
gressive reduction of aneuploid cell lineage in placenta18 because 
only 10% of the cells carried the anomaly. However, the segmental 
trisomies in family P172 were present in only one of the placental 
locations, indicating that these genomic alterations either emerged 
Table 1 | de novo cNVs detected by haplarithmisis










196,885 37 OP/III/V L1 Maternal 65 1/3
P073 Chr 7:13238496–
13348832
110,336 26 OP/III/V L2 Paternal 60 1/3
P080 Chr 3:174684649–
174831994
147,345 32 OP/III/V L3 Maternal 60 1/3
P142 Chr 14:47624206–
47746980
122,774 16 OP/III/V L4 Paternal 70 1/3
P162 Chr 14:64554517–
64953726
399,209 189 OP/III/V L5 Paternal 40 1/3
F351 Chr 22:23250737–
23644794
394,057 99 B/I L6 Maternal – NAe
F351 Chr 4:91709484–
91910883









487,590 45 OP/III/V G1 Paternal 65 1/3
P153 Chr 7:72305671–
74115258
1,809,587 359 B/I L8 Maternal – 3/3
P172 Chr 21:26058246–
48084247
22,026,001 5,796 OP/III/V G2 Paternal 25 1/5
P172 Chr 6:204072–
22569968
22,365,896 4,106 OP/III/V G3 Paternal 10 1/5
P172 Chr 9:135277529–
141031439









361,689 41 B/I L9 Maternal – 3/3
P106 Chr 2:1243048760 243,015,748 44,591 OP/III/V G5 Maternal 10 5/5
F1021 Chr 17:2832092–
3070476
238,384 71 B/II G6 Maternal 40 NAe
a O/T denotes occurrence and type. Occurrence can be B, de novo copy number (CN) alteration occurring in both placenta and umbilical cord DNA samples; OP, de novo copy number alteration occurring in 
placental DNA sample only; and type can be in one of the stratified CNV types illustrated in Fig. 3. b Parent-of-origin is determined based on the parental allele affected; for example, maternal loss or gain means 
that the maternal allele is deleted or duplicated, respectively; for nonmosaic deletions present in both placenta and cord blood, we used the parent-of-origin module of siCHILD to determine parental origin. c 
Percentage of abnormal cells. d CNV/bps denotes number of CNVs found in spatially different placenta biopsies (bps) (see also Extended Data Figs. 2–4). e Further biopsies from these placentae were not available.
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later in gestation through local clonal expansion of aberrant cells 
in the placenta or appeared early in development, contributed to 
the trophectoderm and were largely overgrown by normal cells in 
placental tissue. The presence of multiple de novo DNA copy num-
ber variants has recently been shown to lead to genomic disorders19. 
The finding that multiple CNVs are present with a different degree 
of mosaicism, albeit in the placenta genome only, is indicative that 
they occurred in a cumulative fashion20.
To further investigate CNV heterogeneity across the placenta and 
reaffirm the (non)mosaic nature of the detected de novo CNVs, we 
further analyzed 20 DNA samples derived from spatially different 
locations of all but two placentae (F351 and F1021) with de novo 
CNVs (Table 1). As expected, de novo nonmosaic CNVs found in 
both placenta and cord blood were consistently present in all biop-
sies, whereas de novo mosaic CNVs were not present in the other 
biopsies (Extended Data Fig. 4). Importantly the full Chr 2 mosaic 
trisomy was found in all biopsies (Extended Data Fig. 3), indicating 
its early embryonic origin (see above).
We identified two clinically notable nonmosaic CNVs in the SGA 
cohort, with genetic aberrations found in both umbilical cord and 
placental DNA. P153 carried a de  novo deletion on Chr 7q11.23. 
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OP, placenta only
B, both placenta








































1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22




















































Fig. 2 | Mosaic de novo cNVs and overlap with placental transcriptome. a,b, Haplarithms revealed de novo mosaic partial trisomies in P172 placenta of 
paternal origin (see also Extended Data Fig. 2) (a) and full-chromosome trisomy in P106 placenta of maternal origin (see also Extended Data Fig. 3) (b). 
These aberrations are indicated by purple arrows. c, Validation of detected mosaic de novo CNVs by ddPCR (each circle and error bar indicate mean and 
s.d., respectively, of four independent measurements). d, Placental expression of genes detected in de novo CNV regions, expressed as reads per kilobase 
per million mapped reads (RPKM). CTRL, control.
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syndrome21. P177 carried a paternally inherited duplication on 
Chr 15 with features of Chr 15q13.3 duplication syndrome22,23. The 
low birth weight of these neonates might be indicative of the under-
lying chromosomal aberration; therefore, SGA neonates should be 
subjected to submicroscopic chromosomal analysis.
Although the prevalence of de novo CNVs in SGA (25.0%, 3/12) 
and AGA (12.0%, 6/50) groups of the cohort of natural concep-
tions is not significantly different (P = 0.44, odds ratio test), the 
current sample size for SGA (n = 12) provides limited statistical 
power (<0.50). A study with increased SGA sample size (n > 44; 
see Methods) is required to evaluate the effect of birth weight on 
the prevalence of de  novo CNVs. Furthermore, our data indicate 
that the current sample size (n = 50 per AGA cohort) provides lim-
ited statistical power for detection of CNVs with small effect size 
(w = 0.1–0.2) between the two cohorts. We estimated that future 
studies with smaller effect size would require a dataset of around 
tenfold larger24.
The human placenta is characterized by deep invasion of tro-
phoblasts into the endometrium. Trophoblasts have properties 
similar to cancer cells including rapid proliferation, migration 
and invasiveness. As CIN is a hallmark of both tumorigenesis and 
















Fig. 3 | Schematic representation of plausible occurrence and segregation of de novo cNVs into fetal or placental lineages found in this study. De novo 
CNVs can occur before conception in the germ cells or during conception (I), during the cleavage divisions of early development (II–IV) or later during 
development (for example, blastocyst-stage embryogenesis (V–VI)). Note that, for simplicity in the CIN-derived mosaic CNVs, we merely show CNV burst 
in two-cell-stage embryos (types II–IV) and blastocyst-stage embryos (types V–VI) (see also Table 1). Red circles indicate cells carrying de novo CNV.
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resembles tumor tissue by demonstrating an extensive load of 
de  novo genomic gains, harboring excessively expressed genes 
required for the invasiveness of trophoblasts25. Our results chal-
lenge this view, because we found that placental de novo CNVs were 
present in only 12 of the 111 families (10.8%) (Fig. 1d and Table 1), 
and placental heterogeneity was found in 85.7% (6/7) of the studied 
‘placenta-only’ de novo mosaic CNVs. To determine whether genes 
located in the de novo CNV regions (n = 475) had specific placental 
biology-related functions, we analyzed gene expression in full-term 
placentae following live birth (see Methods). Only 18.1% (n = 86) of 
these genes had moderate or high expression according to whole-
RNA sequencing of placental tissue (Fig. 2d and Supplementary 
Table 4), and genes from regions with de novo gains (18.0%, 77/428) 
and losses (19.1%, 9/47, P = 0.84 odds ratio test) demonstrated simi-
lar proportion of moderate-to-high-expression genes in placental 
tissue. Moreover, enrichment analyses of genes located in de novo 
CNV regions did not reveal any molecular pathway related to pla-
cental biology. All this indicates that these new CNVs are probably 
sporadic and do not play any role in placental biology.
In this study, our main outcome measure was the extent and prev-
alence of de novo large CNVs (>100 kb) in live-born IVF-conceived 
neonates when compared to naturally conceived ones. Although 
we have not studied the embryonic loss with or without aneuploi-
dies in IVF or in naturally conceived pregnancies, we speculate that 
when all cells of day-3 (cleavage-stage) embryos are investigated for 
the presence of (segmental) aneuploidies, on average 80% of the 
embryos present with at least one aneuploid cell (range, 70–90%)1,3,10. 
The IVF success rate per embryo transfer of day-3 embryos is about 
35% in the Helsinki and Tartu IVF centers. Assuming that all euploid 
day-3 embryos survive, these would constitute, at most, 20% of the 
total number of embryos transferred resulting in pregnancy/deliv-
ery, but indicating that at least 15% of all embryos did contain some 
aneuploid cells. This would amount to 60 and 40% of the live births 
resulting from, respectively, euploid and mosaic euploid/aneuploid 
cleavage-stage embryos. Conversely, about 20% (15/80) of mosaic 
embryos survive and result in healthy live births whereas 80% (65/80) 
are selected against. Since it is unlikely that all euploid embryos make 
it to term, the latter is a lower estimate.
Mosaicism rates in human IVF embryos are still debated and 
vary across studies, primarily because of the definition of mosaicism 
used, the technology applied and the variance in assisted reproduc-
tion protocols used. First, important differences in the definition of 
a mosaic embryo exist among studies. Embryos having both euploid 
and aneuploid cells were defined as mosaic in 1993 (ref. 26) but, since 
then, an arbitrary classification of embryos as mosaic or diploid 
has influenced the mosaicism rate reported by different studies. 
For instance, some studies27–29 considered an embryo mosaic only 
if >50% of blastomeres within the embryo were aneuploid. The 
reason for considering an embryo having <50% abnormal cells as 
diploid was that they are probably viable, and a low percentage of 
abnormal cells in those embryos was believed clinically irrelevant. 
Second, since the discovery of aneuploidies in human preimplan-
tation embryos30,31, different technologies have been used to pro-
file their chromosomal constitution. Depending on the technology 
used, the rate of mosaicism was reported to range from 15% (ref. 32) 
to >90% (refs. 1,3). However, in a meta-analysis of all technologies 
included and carried out on 815 embryos from different develop-
mental stages, 73% were classified as mosaic10. High variability 
occurs because different technologies have different sensitivities 
and specificities for profiling the ploidy state of a selected chromo-
somes (for example, FISH32) or the entire genome (microarray1,3 
or next-generation sequencing3,33). The foregoing, and the number 
of cells per embryo analyzed with those technologies, can affect 
the reported embryo mosaicism rates in studies, with those stud-
ies analyzing all cells from a single embryo showing higher rates 
of mosaicism10. In the current study, we applied the same wet- and 
dry-lab technologies as in our preimplantation embryo studies3,34,35 
and further validated our approach using sensitive ddPCR and 
standard copy number analysis methods36,37, allowing us to rule 
out technology-driven bias. Third, the mosaicism rate is reported 
to be influenced by the fertility clinic where the IVF procedure is 
carried out38; one key component that can explain differences in the 
reported mosaicism rate is embryo culture conditions39. However, 
in this study, the IVF procedure, including culture conditions, 
was similar throughout the participating IVF clinics.
Taken together, our findings suggest that the high level of chro-
mosomal mosaicism in IVF cleavage-stage embryos is not preserved 
at later stages of prenatal development. Although we found a low-
level mosaic trisomy in one IVF placental genome, it was not present 
in the fetal lineage of the same pregnancy, suggesting a proliferative 
defect of trisomic cells. The sporadic de novo genomic aberrations 
found in approximately 10.8% of pregnancies were scattered across 
the genome and represented random and rare events of embryonic 
CIN, without any observed functional consequence on placental 
biology or fetal health. Thus, our findings confirm that the IVF pro-
cedure has no detrimental effect on large genomic rearrangements 
in fetal and placental lineages of live-born neonates, which helps 
to remove a major health concern in regard to IVF neonates.
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Methods
Ethical approval. The study was approved by the local Ethics Committee of the 
University of Tartu (no. 213/T-21) and the Ethics Committee of Helsinki University 
Central Hospital (no. 285/13/03/03/2013). All couples signed the appropriate 
informed consent form.
Selection of participating families. In total, 111 couples participated in this study 
(Supplementary Tables 1 and 2), including 62 couples who delivered neonates 
after spontaneous conception (natural cohort) and 49 couples who delivered after 
IVF (IVF cohort). No previous genetic predisposition was identified in any of 
the couples participating in this study. Clinical data and biological material were 
collected from singleton pregnancies at birth from vaginal delivery or cesarean 
section (Supplementary Table 2). For each family, we isolated DNA from the 
father and mother, as well as from the placenta and neonate umbilical cord blood, 
following live birth (quartet DNA sample set). The natural cohort was divided 
into two subgroups based on neonate birth weight: (1) AGA neonates with a birth 
weight between the tenth and 90th percentiles (n = 50 families), and (2) SGA 
neonates with a birth weight below the tenth percentile (n = 12 families). The IVF 
cohort consisted of 48 families with AGA neonates and one family with an SGA 
neonate. Birth weight percentiles were calculated using data from the Estonian 
Medical Birth Registry40 and the Finnish National Institute for Health and Welfare41.
Sample collection and DNA extraction. Full-thickness placental blocks of 
around 1 cm were taken from placenta and stored at −80 °C for subsequent 
DNA extraction. To investigate placental CNV heterogeneity, we analyzed 
between three and five biopsies from spatially distinct locations of ten placentae 
(Table 1 and Extended Data Figs. 2–4). All samples were collected by the same 
medical personnel. Maturity and health of term placentae were confirmed by 
histological examination. A total of 9 ml peripheral venous blood from parents 
and 4 ml umbilical cord blood were collected into EDTA-containing tubes (BD 
Vacutainer, Becton, Dickinson and Co.). In Estonia, DNA was isolated from 
blood and placental tissue using the PureLink Genomic DNA Kit (Invitrogen, Life 
Technologies). DNA samples were eluted with 200 µl PureLink Genomic Elution 
Buffer (10 mM Tris-HCl pH 9.0, 0.1 mM EDTA) and stored at −20 °C until analysis. 
Finnish parental DNA from blood samples was extracted by NucleoSpin Blood XL 
Kit (Macherey-Nagel), and DNA from umbilical cord blood by NucleoSpin Tissue 
Kit (Macherey-Nagel). NanoDrop 2000 (Thermo Fisher Scientific, Inc.) was used 
to assess DNA concentration and purity.
SNP genotyping. For SNP genotyping, the Infinium PsychArray-24 v.1.1 
(Illumina, no. GEO: GPL22819) and PsychArray-24 v.1.3 BeadChip SNP arrays 
(Illumina, no. GEO: GPL26750) were used, which contain approximately 
590,000 SNP markers with a median marker spacing of 5.5 kb. Genotype calls,  
SNP B-allele frequency values and logR values of all samples were computed  
using Illumina GenomeStudio software.
Haplarithmisis. We applied haplarithmisis3 on each quartet DNA sample. 
Discrete SNP calls derived from umbilical cord blood were used as seeds to 
phase the parental genotypes. Parental haplarithms were used to infer DNA copy 
number state, parent-of-origin and level of mosaicism of de novo copy number 
alterations in placental/newborn DNA. Levels of mosaicism were calculated as 
previously described42.
Haplarithmisis can be used to estimate the contributions of maternal and 
fetal genomes in placental DNA samples. We carried out a simulation analysis by 
blending maternal and fetal alleles in different proportions (from 1%mother/99%child 
to 99%mother/1%child) and applied haplarithmisis (Extended Data Fig. 5). This process 
allowed accurate determination of maternal and fetal contributions to placental 
tissue (Supplementary Table 5 and Extended Data Fig. 1).
Copy number profiling. We applied both PennCNV36 (with 0.2% false-positive 
rate and 86% sensitivity for constitutional CNVs) and QuantiSNP37 (with 0.1% 
false-positive rate for constitutional CNVs) algorithms, as well as the copy number 
module of siCHILD3 on the raw logR values, with minor modifications. Raw logR 
values were smoothed using a moving average window of five consecutive SNP 
probes, wave-corrected for GC% bias by a Lowess fit and normalized to a trimmed 
mean of normal diploid chromosomes. Normalized logR values were segmented 
by piecewise-constant fitting43 (γ = 14). A copy number alteration was considered 
reliable if (1) more than six consecutive SNP probes supported the copy number 
change, (2) its length was >33 kb (sixfold 5.5-kb median distance between two 
probes) and (3) it was supported by raw or segmented parent-of-origin specific 
haplotypes, coined haplarithms. As a sanity check, we investigated whether there 
were signals detected only by haplarithmisis (Supplementary Table 6) or logR 
analysis (Supplementary Table 7). We did not include those in the analysis.
Copy number analysis was empowered by our quartet sample set and 
haplarithmisis, as we used all of the samples within a quartet to call a reliable 
genomic change. For each of the detected DNA copy number alterations in  
one sample (for example, placenta), we checked whether the same alteration  
was present in other samples of the same quartet. This approach allowed us  
to determine the parental origin of inherited CNVs, to detect de novo CNVs  
(that is, in placental samples or in both placental and umbilical cord samples), 
to find CNVs exclusive to any of the samples (for example, present solely in the 
placental genome) and to reveal genotyping artifacts.
Other statistical and computational analysis. Since both predictor (with or 
without IVF treatment) and outcome (with or without de novo CNVs) are 
dichotomous, chi-squared is the most suitable test44. To determine appropriate 
sample size, we performed a power analysis using chi-squared test with confidence 
level of at least 95% and feeding the conventional effect size (w) values of 0.1, 0.3 
and 0.5, which correspond to small, medium and large effect sizes, respectively45. 
With a medium effect size, at least 40 samples per cohort are required to reach the 
power of 0.8 (ref. 24). Given the sample size of about 50 per cohort (50 naturally 
conceived quartets and 48 IVF quartets with appropriate birth weight for 
gestational age), this study has >80% power (α = 0.05, middle effect size = 0.3;  
case-to-control ratio ≈ 1) to detect a significant difference (<0.05).
We also compared large CNVs with mosaic or nonmosaic nature separately. 
The rates of mosaic large CNVs found in naturally versus IVF-conceived AGA 
groups were not significantly different (P = 0.157, Pearson’s chi-square test). 
Similarly, the rates of nonmosaic CNVs found in naturally versus IVF-conceived 
AGA groups were not significantly different (P = 0.977, Pearson’s chi-square test).
We applied Hotelling’s T2 multivariate statistical test on the numerical 
demographic features of AGA neonates of both IVF and natural cohorts, 
including birth weight, birth length, placenta weight, parity and gestational 
age. This analysis showed no significant difference in these cohorts (P = 0.22, 
Hotelling’s two-sample T2-test).
For statistical analyses we applied R (http://www.r-project.org/). For 
visualization purposes we applied siCHILD3 and R (http://www.r-project.org/).
RNA sequencing and comparison to placental transcriptome. We performed 
RNA sequencing as described previously46 (Supplementary Table 4). Briefly, 
12 placental samples were collected from singleton pregnancies at term (range, 
38–42 weeks of gestational age). Placental samples from different families were 
used for RNA sequencing and CNV analysis. Full-thickness placental blocks of 
around 2–3 cm were taken from three different regions of placenta. Total RNA was 
extracted with the mirVana miRNA Isolation Kit (Ambion, Life Technologies), and 
RNA samples were pooled. DNA contamination was removed with the DNA-free 
Kit (Invitrogen, Life Technologies). Agilent 2100 Bioanalyzer and RNA 6000 Nano 
Kit (Agilent Technologies) were used to assess the integrity and concentration of 
total RNA samples.
For RNA-seq library preparation, 45 ng total RNA was amplified with the 
Ovation RNA-seq System V2 Kit (NuGen). The SOLiD 5500 System DNA 
fragment library (Life Technologies) was used for library preparation. Pooled 
samples were analyzed on three FlowChip lanes, and approximately 40 million 
mappable paired-end reads were obtained per sample. DESeq (v.3.0.2) was used 
to calculate reads per kilobase per million (RPKM). All genes from placenta were 
grouped into four classes according to their RPKM value (0–1, 1–10, 10–100 and 
>100). Genes with moderate to high expression were defined by more than ten 
mapped reads per RPKM and treated as placenta-expressed genes.
Protein-coding genes from de novo CNV regions were extracted from the 
University of California, Santa Cruz browser (https://genome.ucsc.edu/). Human 
genome build GRC37/hg19 was used as a reference. Genes found at de novo CNV 
regions were studied for gene expression in placental tissue from 12 individuals. 
Enrichment analyses for Gene Ontology terms were performed for genes present 
at de novo CNVs, using g:Profiler (v.Ensembl 90, Ensembl Genomes 37, rev 1741, 
build date 19 October 2017)47 with default settings. Briefly, this tool performs 
gene set enrichment analyses for Gene Ontology, Human Phenotype Ontology 
and Kyoto Encyclopedia of Gene and Genomes gene sets. Enrichment analyses 
were conducted by hypergeometric test, and resulting enrichment P values were 
further adjusted for multiple testing by the g:SCS (Set Counts and Sizes) method, 
developed to address the nonindependent structure of tested Gene Ontology 
terms47. Separate enrichment analyses were conducted for different groups of genes 
based on cohort, CNV type and expression in placenta (all genes and placenta-
expressed genes). Results were filtered hierarchically, and only the most significant 
ontology per parent group is shown. De novo CNVs with gains and losses were 
analyzed separately.
Validation by ddPCR. We applied ddPCR to validate low-level mosaic aberrations 
(Fig. 2c and Supplementary Table 3). We used a proof-of-principle assay to 
evaluate the sensitivity of TaqMan-based ddPCR. A DNA sample from a trisomy 21 
(copy number, 3) cell line was mixed with a DNA sample from a normal diploid 
cell line (copy number, 2) at different ratios, creating admixture series of DNA 
samples with 100, 75, 50, 25, 10–15 and 0% abnormal alleles (Extended Data 
Fig. 6). The cell lines of Epstein–Barr virus-immortalized lymphocytes had been 
established in-house using blood samples from patients at the Centre for Human 
Genetics, UZ Leuven, Leuven, Belgium, and were authenticated by conventional 
karyotyping. Mycoplasma PCR was performed to ensure that the cell lines were not 
contaminated48. To evaluate the level of Chr 21 mosaic gain, the FAM-fluorescent 
TaqMan copy number assay probe for the RUNX1 gene locus (dHsaCP1000308) 
was used as a target probe. The HEX-fluorescent TaqMan copy number reference 
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assay AP3B1 probe (dHsaCP2500348) was used as an internal reference control 
(Bio-Rad).
The ddPCR system was operated according to the manufacturer’s instructions. 
Briefly, before droplet generation, restriction enzyme HaeIII (New England 
Biolabs, Inc.) was added directly to the ddPCR reaction mixture and incubated 
for 20 min at room temperature. Subsequently, droplets were generated in a DG8 
disposable droplet generator cartridge using a QX100 Droplet Generator (Bio-Rad).  
PCR amplification was performed using the following conditions: 95 °C for 
10 min, followed by 40 cycles of 94 °C for 30 s and 59 °C for 1 min and, finally, 98 °C 
for 10 min. Droplets were counted using the QX100 Droplet Reader. Data were 
analyzed using QuantaSoft Software (Bio-Rad).
Mosaic ratio was calculated based on the total positive signal counts of 
RUNX1 normalized against reference AP3B-positive signal counts. All analyzed 
samples were run in four-replicate reactions. Mosaic placental DNA samples were 
processed in the same manner by performing initial DNA digestion, followed 
by droplet generation and PCR amplification. All DNA samples were quantified 
using the TaqMan copy number assay target probes for the specific gene in the 
region of interest. The AP3B1 probe was used as an internal reference control 
(Supplementary Table 3).
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
data availability
All SNP array data generated in this study were deposited in the NCBI Gene 
Expression Omnibus under accession no. GSE93353.
code availability
Custom code is available from the author upon reasonable request.
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Extended Data Fig. 1 | Haplarithmisis revealed maternal and fetal contributions to placental dNA samples. We show density of paternal (in blue)  
and maternal (in red) distances computed from paternal and maternal haplarithms, respectively, of the placenta and cord blood samples of P154, P109, 
P162 and P116 (see also Fig. 1b and Source data).
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Extended Data Fig. 2 | The mosaic partial trisomies are not preserved across the P172 placenta. The mosaic partial trisomies (purple arrows) on Chr6, 
Chr9 and Chr21 are only present in one biopsy (Biopsy I) out of all the spatially different biopsies of P172 placenta.
NATuRE MEdIcINE | www.nature.com/naturemedicine
Letters Nature MediciNe
Extended Data Fig. 3 | The full chr 2 mosaic trisomy is persistently present across the P106 placenta. The full Chr 2 mosaic trisomy (purple arrows) is 
persistently present in all the spatially different biopsies of P106 placenta.
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Extended Data Fig. 4 | Placenta cNV heterogeneity. We analyzed dNA samples from spatially distinct biopsies across the placentas. a, the de novo  
non-mosaic CNVs were consistently present in all the biopsies (P153 and P091). b, the mosaic CNVs were present in one biopsy (P080 and P070), 
indicating placental mosaic CNV heterogeneity (see also Extended Data Fig. 2 and Source data).
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Extended Data Fig. 5 | determining fetal and maternal compartments in placenta dNA-samples using haplarithmisis. We performed an in silico simulation 
by combining genotypes of the child and the mother with different proportions (from 1%Mother : 99%Child to 99%Mother : 1%Child) and deduced 
haplarithm profiles for each of these combinations, representing fetal and maternal compartments in placenta DNA samples (see also Source data).
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Extended Data Fig. 6 | Proof-of-concept assay for the detection of mosaic aberrations using droplet digital PcR. We mixed up a DNA sample from a 
trisomy 21 (copy number, CN=3) cell line with a DNA sample derived from a normal diploid cell line (CN=2) at different ratios, creating admixture series 
of DNA samples with 100%, 75%, 50%, 25%, 10–15% and 0% of abnormal alleles. Mosaic DNA samples were normalized to the number of fully diploid 
control (i.e. 0% abnormal). Each circle and error bar indicate mean and standard deviation, respectively, of four independent measurements.
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When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main 
text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one- or two-sided 
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND 
variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
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For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
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Software and code
Policy information about availability of computer code
Data collection We have generated new data in this study. Specifically, following birth, we scrutinized genome-wide single nucleotide polymorphism 
(SNP) profiles in DNAs from the father, mother, placenta and neonate umbilical cord blood of 111 families (i.e. 111 quartets). For SNP 
genotyping, the Infinium PsychArray-24 v1.1 (Illumina; GEO: GPL22819) and PsychArray-24 v1.3 BeadChip SNP arrays (Illumina; GEO: 
GPL26750) were used, which contains approximately 590,000 SNP markers with a median marker spacing of 5.5 kb. No software has 
been used for data collection.
Data analysis We developed a web platform that is freely available for research only (see the web platform at: https://hiva.esat.kuleuven.be/). Custom 
code for detecting fetal and maternal compartments is available upon request. Genotype calls, SNP B-allele frequency values and logR 
values of all samples were computed by the Illumina GenomeStudio 2.0 software. PennCNV and QuantiSNP were used for standard copy-
number analysis and comparison with our detected CNVs. Haplarithmisis of siCHILD was used to compute parental haplarithms. Copy 
number module of siCHILD on the raw logR values was used with minor modifications. Raw logR-values were smoothed by using a 
moving average window of five consecutive SNP probes, wave-corrected for GC% bias by a Lowess fit and normalized to a trimmed mean 
of normal diploid chromosomes. Normalized logR-values were segmented by piecewise-constant fitting (gamma = 14). For statistical 
analyses we applied R version 3.6.0, including packages stats, fmsb (v0.6.3), ICSNP (v1.1-1), ICS (v1.3-1) and TrialSize (v1.3). g:profiler 
release 2017-10-19 were used for enrichment analyses.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers 
upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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Policy information about availability of data
All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: 
- Accession codes, unique identifiers, or web links for publicly available datasets 
- A list of figures that have associated raw data 
- A description of any restrictions on data availability
All SNP array data generated in this study were deposited in the 
NCBI Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/) under accession number GEO: GSE93353.
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For a reference copy of the document with all sections, see nature.com/authors/policies/ReportingSummary-flat.pdf
Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size Since both predictor (with or without IVF treatment) and outcome (with or without de novo CNVs) are dichotomous, chi-squared test is the 
most suitable test. To determine appropriate sample size, we performed a power analysis using chi-squared test with confidence level of at 
least 95% and feeding the conventional effect size (w) values of 0.1, 0.3 and 0.5, which correspond to small, medium and large effect sizes, 
respectively. With a medium effect size (w=0.3) at least 40 samples per cohort is required to reach to the power of 0.8.
Data exclusions No data were excluded from the analysis.
Replication For 10 placenta samples we had 3-5 biological replicates, i.e. from spatially different locations of the placenta (see Table 1). This was to 
further investigate CNV heterogeneity across the placenta and reaffirm the (non-)mosaic nature of the detected de novo CNVs. For that, we 
further analysed 20 DNA samples derived from spatially different locations of all but two placentas (F351 and F1021) with de novo CNVs 
(Table 1). As expected, de novo non-mosaic CNVs found in both placenta and cord blood were consistently present in all the biopsies, whereas 
de novo mosaic CNVs were not present in the other biopsies (Extended Data Fig. 4). 
Randomization The study participants were not randomized, but they were rather divided to IVF and naturally conceived families.
Blinding Prior to data analyses all the quartets were anonymized.
Reporting for specific materials, systems and methods
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Policy information about availability of materials
Obtaining unique materials The majority of unique materials, including DNA samples from father, mother, placenta and umbilical cord (i.e. quartets) used, 
are readily available from the authors. 
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Policy information about studies involving human research participants
Population characteristics In total, 111 couples participated in this study (Supplementary Table 1 and 2), including 62 couples, who delivered neonates 
after spontaneous conception (natural cohort) and 49 couples who delivered after IVF (IVF cohort).
Recruitment No prior genetic predisposition was identified in any of the couples participated in this study. In addition, the transferred 
embryos of IVF newborns were not screened nor counter selected for chromosomal aneuploidy status before intrauterine 
transfer. The families enrolled in the current study were consecutively recruited.
